Dataset Information

Recombinant CD52 Glycopeptide data

ABSTRACT: Recombinant soluble human CD52 was produced in HEK293 cells and tested for immunosuppressive activity.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Suspension Culture

SUBMITTER: Nicholas DeBono

LAB HEAD: Nicolle H Packer

PROVIDER: PXD056562 | Pride | 2025-05-07

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	FXa_PNGase_frac_noNG_CD52_17.raw	Raw
	FXa_PNGase_frac_noNG_CD52_18.raw	Raw
	FXa_PNGase_frac_noNG_CD52_19.raw	Raw
	FXa_PNGase_frac_noNG_CD52_20.raw	Raw
	FXa_PNGase_frac_noNG_CD52_21.raw	Raw

Items per page:

1 - 5 of 39

Publications

The molecular basis of immunosuppression by soluble CD52 is defined by interactions of N-linked and O-linked glycans with HMGB1 box B.

DeBono Nicholas J NJ D'Andrea Silvia S Bandala-Sanchez Esther E Goddard-Borger Ethan E Zenaidee Muhammad A MA Moh Edward S X ESX Fadda Elisa E Harrison Leonard C LC Packer Nicolle H NH

The Journal of biological chemistry 20250225 4

Human soluble CD52 is a short glycopeptide comprising 12 amino acids (GQNDTSQTSSPS) which functions as an immune regulator by sequestering the pro-inflammatory high mobility group box protein 1 (HMGB1) and suppressing immune responses. Recombinant CD52 has been shown to act as a broad anti-inflammatory agent, dampening both adaptive and innate immune responses. This short glycopeptide is heavily glycosylated, with a complex sialylated N-linked glycan at N3 and reported O-linked glycosylation pos ...[more]

PMID: 40015632

Similar Datasets

Project description:The Human Induced Pluripotent Stem Cells Initiative (HipSci) is generating a large, high-quality reference panel of human IPSC lines. This is a pilot submission of mass-spectrometry analyses from 18 induced pluripotent stem cell lines generated by the HipSci project. This submission includes also data for two embryonic stem cell lines, and one reference sample comprising a mixture of 42 IPSC lines. Associated BioSamples accessions: <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2397999">SAMEA2397999</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398167">SAMEA2398167</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398916">SAMEA2398916</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2397948"> SAMEA2397948 </a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2399112">SAMEA2399112</a>,<a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2399257">SAMEA2399257</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398553">SAMEA2398553</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398821">SAMEA2398821</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398316">SAMEA2398316</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2469778">SAMEA2469778</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2399037">SAMEA2399037</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398656">SAMEA2398656</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398428">SAMEA2398428</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2469777">SAMEA2469777</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2397959">SAMEA2397959</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398442">SAMEA2398442</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398024">SAMEA2398024</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA2398450">SAMEA2398450</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA3402864">SAMEA3402864</a>, <a href="http://www.ebi.ac.uk/biosamples/sample/SAMEA3110364">SAMEA3110364</a>

Project description:Background Plasma proteins can be modified by addition of sugar residues by non-enzymatic glycation as well as glycosylation. While glycation is a hallmark of hyperglycemia, glycosylation is a complex, enzyme-catalyzed post-translational modification by heterogeneous sugar chains and is present on a majority of plasma proteins. N-linked glycosylation occurs on asparagine residues occurring predominantly on a canonical N-glycosylation motif (Asn-X-Ser/Thr) although non-canonical N-glycosylation motifs Asn-X-Cys/Val have also been reported to be glycosylated less frequently. Albumin is the most abundant protein in human plasma whose glycation has been implicated in end-organ damage in advanced diabetes mellitus, and as such, has both diagnostic and therapeutic implications. However, albumin has long been regarded as a non-glycosylated protein owing to the absence of canonical motifs. Albumin contains two non-canonical N-glycosylation motifs, of which one was recently reported to be glycosylated with two possible attached glycans. Methods To investigate N-linked glycosylation of abundant serum proteins in greater detail, we passed healthy donor samples through a multiple affinity removal spin (MARS14) column followed by trypsin digestion of bound proteins and subsequent glycopeptide enrichment by size-exclusion chromatography (SEC) or mixed-mode anion-exchange (MAX), in parallel. Global analysis of intact glycopeptides was performed by LC-MS/MS to evaluate potential glycosylation at canonical as well as non-canonical sites. PNGase F treatment was carried out to confirm N-linked glycosylation at non-canonical sites Asn-X-Cys/Val. Glycopeptides on albumin at non-canonical sites were further characterized by MS3 fragmentation from immunoprecipitated albumin to confirm the attached glycans. To assess if the observed glycosylation was a general phenomenon, targeted analysis using parallel reaction monitoring (PRM) was carried out on an independent set of twenty human serum samples. Finally, to test whether albumin glycosylation is unique to human albumin or is a general phenomenon, bovine and rabbit serum albumins were subjected to MAX chromatography and LC-MS/MS analysis. Results We report that human albumin is modified by N-linked glycosylation at two sites, Asn68(-Glu-Val) and Asn123-(Glu-Cys), both of which occur in non-canonical N-glycosylation motifs. We detected N-glycopeptides at both sites bearing four complex mono- and bi-antennary N-linked glycans, with Hex5HexNAc4NeuAc2 and Hex5HexNAc4NeuAc1 being the most abundant glycans. These findings were validated by analyzing deglycosylated peptides and MS3-based fragmentation of glycopeptides. Glycosylation at both sites was confirmed by targeted MS in twenty donor samples. Finally, we report that the Asn residue on bovine and rabbit serum albumins that corresponds to the highly conserved Asn123 in human albumin is also N-glycosylated with complex sialylated glycans similar to those observed in human albumin. Conclusions Albumin is a conserved glycoprotein with multiple N-linked glycosylation sites. This glycosylation of albumin has potential functional implications and applications in medicine.

Project description:RationaleWe report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi). The method has been optimised to produce peptides with single, isolated glycosylation sites using multiple protease digests. The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.MethodPurified spike proteins were reduced, alkylated, and digested with proteolytic enzymes. Three different protease digests were utilised to generate peptides with isolated glycosylation sites. The glycopeptides were then analysed using a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment. Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.ResultsTwo different spike proteins from 6 manufacturers were analysed. There was a strong similarity at each site across batches and manufacturers. The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins. A comparison was performed on a commercially available spike protein and our results were found to be similar to earlier reports.ConclusionOur data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities. The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein. We compared our method with previously obtained data from a commercially available insect cell derived spike protein and the results were comparable to published findings.

Project description:The most common congenital disorder of glycosylation (CDG) is caused by pathogenic variants in PMM2 (PMM2-CDG) that reduce phosphomannomutase activity and impair N-glycan synthesis. Patients present early in life with multi-system disabilities. Traditional diagnosis relies on measuring carbohydrate-deficient transferrin (CDT) and confirmation by genetic testing. However, tests for CDT can be normal in some patients, or normalize with age. Because patients also show subtle alterations in serum glycan structures, we considered that site-specific glycosylation changes might be diagnostic. We analyzed serum from 35 individuals with PMM2-CDG for discovery and validation of glycoproteomic changes. We carried out mass spectrometry-based discovery studies to profile the glycoproteome in an initial set of well-characterized affected individuals and matched controls. Next, we developed a streamlined method for analyzing additional affected individuals. Finally, targeted mass spectrometry was used to validate selected N-glycopeptides in an independent set of samples in a blinded fashion. Of the 3,342 N-glycopeptides derived from 284 glycoproteins identified in discovery experiments, individuals with PMM2-CDG exhibited a general decrease in complex-type N-glycans and an increase in truncated, mannose-rich and hybrid species. We identified a glycopeptide from complement C4 carrying the glycan Man5GlcNAc2, which was not detected in controls. Notably, this glycopeptide was also detected in five affected individuals with normal CDT, including one individual after liver transplant, two individuals with a known genetic variant associated with mild disease and two individuals with well characterized variants, indicating that this glycopeptide is more sensitive than CDT. Finally, this marker was also detected by targeted analysis in two individuals with variants of uncertain significance (VUS) in PMM2 gene. Overall, we believe that C4-derived Man5GlcNAc2 glycopeptide could serve as a novel next-generation biomarker for more accurate diagnosis and tracking progress of patients in therapeutic trials.